Disc Medicine Reports Strong Clinical Data for Key Hematology Programs at EHA 2026
Event summary
- Disc Medicine presented positive Phase 2 data for DISC-0974 in myelofibrosis anemia, showing durable responses across patient subgroups.
- Bitopertin demonstrated sustained PPIX reductions and improved light tolerance in EPP patients in the HELIOS trial.
- Company plans End of Phase 2 discussions with FDA for DISC-0974 by year-end and APOLLO Phase 3 readout for bitopertin in Q4 2026.
- Initial data from RESTORE-PV trial of DISC-3405 in polycythemia vera expected in Q4 2026.
The big picture
Disc Medicine's positive EHA 2026 data reinforces its position in hematology, with three programs potentially in pivotal development by 2027. The company's focus on heme biosynthesis and iron homeostasis targets a critical unmet need in rare blood disorders, positioning it for potential regulatory milestones in the second half of 2026. The clinical progress across its portfolio highlights the strategic shift toward addressing multiple hematologic diseases through novel biological pathways.
What we're watching
- Regulatory Pathway
- Whether the APOLLO Phase 3 results for bitopertin can support a traditional approval and address the CRL.
- Pipeline Momentum
- The pace at which DISC-3405 advances toward pivotal development in 2027.
- Clinical Execution
- How DISC-0974's Phase 2 data will influence End of Phase 2 discussions with FDA.